New UK Survey Shows Improving Patient Perceptions of Pharma

A recent PatientView survey of 106 UK patient organizations revealed significant shifts in how pharmaceutical companies are perceived by patient groups. Among organizations that actively work with pharma companies, GSK climbed five places to take the top spot for corporate reputation, while AbbVie made one of the biggest jumps in the rankings, rising ten places to secure second position. Boehringer Ingelheim rounded out the top three. AstraZeneca and Merck & Co. also posted notable gains.

At first glance, reputation rankings may seem more relevant to corporate affairs teams than healthcare marketers. In reality, these findings offer valuable insights into how engagement strategies are evolving across the industry.

Patient groups increasingly evaluate pharmaceutical companies on factors such as transparency, patient centricity, quality of engagement, access to medicines, and the perceived value of their products. Companies that perform well in these areas are often the same organizations investing heavily in long-term stakeholder engagement rather than relying solely on product-focused communications.

The results are particularly interesting because they highlight how quickly perceptions can change. AbbVie's dramatic rise and GSK's move to the top of the rankings demonstrate that reputation is not static. Patient organizations are continually reassessing companies based on their actions, partnerships, communication efforts, and responsiveness to patient needs.

For healthcare marketers, this serves as an important reminder that physician engagement does not happen in isolation. Physicians, patient advocates, healthcare systems, and policymakers increasingly operate within the same information ecosystem. A company's reputation among patients can influence how stakeholders view its educational initiatives, disease awareness campaigns, and broader contributions to healthcare.

The findings also align with a broader trend emerging across healthcare communications. As scientific information becomes more accessible and stakeholders become more interconnected, trust is becoming a critical differentiator. Successful engagement strategies are no longer measured solely by reach or impressions. They are increasingly measured by credibility, relevance, and the ability to build meaningful relationships over time.

The good news for the industry is that overall perceptions of pharma appear to be improving. According to the survey, 56% of UK patient groups rated the industry's reputation as good or excellent, the highest level reported in recent years. While challenges around access, affordability, and transparency remain, the results suggest that many organizations are making progress in strengthening relationships with the communities they serve.

For HCP marketers and engagement leaders, the lesson is clear. In an increasingly connected healthcare environment, reputation is not simply a corporate metric. It is an engagement asset. Companies that earn trust across multiple stakeholder groups are often better positioned to capture attention, foster meaningful dialogue, and build lasting influence throughout the healthcare ecosystem.

G-Med excels in HCP marketing by blending digital innovation with data-driven insights, creating an effective platform for reaching healthcare professionals, offering various advertising solutions. By using G-Med to engage HCPs, share data reports, and explore innovative channels, marketers can deliver targeted, impactful messages that foster strong connections. G-Med’s approach ensures that each campaign is tailored, scientifically rigorous, and effective, aligning perfectly with the best practices for successful HCP marketing.   

Contact us today to learn more: Contact@g-med.com